knowledge score among trainees (p<0.05). The project has also provided a platform for sharing experiences and maintaining partnerships with regional and international institutes in addition to provision of technical support for newly established RECs.

Conclusion We believe that the array of activities conducted through this project had enhanced the governance, coordination, feasibility and, efficiency of the ethical review system in Sudan.

**Abstracts**

**OC 8717** TRANSFER OF LEADERSHIP, WHAT DO WE NEED?
Stellah Mpagama. Kilimani Hospital, Kilimanjaro, Tanzania

**Background** The Pan African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) was designed to build clinical tuberculosis (TB) trial capacity whilst conducting clinical trials investigating novel and existing agents to shorten and simplify TB treatment. One of the objectives of the programme is to foster leadership development in sub-Saharan TB-endemic countries to move leadership to African partners in the PanACEA research programmes.

**Methods and results** In PanACEA 1 the participation of the sites on the consortium board was important to foster leadership development. African investigators now make up a large part of the consortium leadership and are actively developing new concepts. Delegates of the sites visited the annual PanACEA General Assembly meetings, where they could gain knowledge, actively participate in the meetings and discussions and network with others from the TB research community. Various sites participated at TB research community conferences (e.g. CROI, Lung Health Meeting) where PanACEA members gave presentations and could collaborate with other TB trial networks.

In PanACEA 2 all clinical trials are co-led by a European established researcher and an African Principal Investigator (PI), to ensure that African scientists are trained and mentored to lead in every aspect essential to clinical trial delivery, from trial and data management to statistical analysis and trial design, and from financial management to laboratory science. The capacity development cores, which serve as operational support for all PanACEA studies and provide high level oversight, also use the European and African countersystem, including senior and junior co-chairs among the African trial sites.

An example of a leadership transfer is a large EDCTP application for the development of a new compound in MDR TB (FACE-MDR-TB) in which Stellah Mpagama is the lead applicant.

**Conclusion** The PanACEA consortium has actively facilitated a transfer of leadership programme which may be successful in future consortia.

**OC 8721** WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPlicated MALARIA IN WEST AND CENTRAL AFRICA

1Abdoulaye Djimde*, on behalf of the WANECAM II consortium, 2Martin P Grobusch, 3Reilla Zoleko Manego, 4Gysiain Monmo-Ngoma, 5Stephanie Picot, 6Isaaka Sagara, 7Colin Sutherland, 8Aminatou Kone, 9Ogobara K Doumbou, 10Jose Pedro Gil, 11Anders Björkman, 12Stephanie Bornmann, 13Issaka Soulama, 14Bakary Foliana, 15Stephan Duparc, 16Alasane Dicko, 17David Hughes, 18Comelis Winss, 19Sodomou B Sirima, 20Eric Adelhossi, 21Jean-Bosco Ouedraogo, 22Laurent Dembele, 23Isaaka Zongo, 24Sophie Biguenet, 25Edike Ilboudo-Sanogo, 26Aminata Foliana. 1Université des Sciences, 2Techniques et des Techniques de Bamako (USTTB), Mali; 3Groupe de Recherche Action en Santé (GRAS), Burkina Faso; 4Institut des Sciences et Techniques (INSTech), Ouagadougou Burkina Faso; 5Centre de Recherches Médicales en Lambaréné (CERMI), Libreville, Gabon; 6University Abdou Moumuni of Niamey, Niger; 7Academic Medical Center (AMC), Amsterdam, The Netherlands; 8University Lyon 1, France; 9London School of Hygiene and Tropical Medicine, UK; 10Karolinska Institute (KI), Stockholm, Sweden; 11Novartis Pharma AG, Basel, Switzerland; 12Medecines for Malaria Venture (MMV), Geneva, Switzerland; 13Eberhard Karls Universität Tübingen, Germany

**Background** Despite major progress in the past decade, malaria remains a major public health problem in sub-Saharan Africa. West and Central Africa account for nearly 2/3 of the burden currently attributable to falciparum malaria. Artemisinin-based...